Last update 21 Nov 2024

Neurotrophic factor-producing mesenchymal stem cell therapy (BrainStorm Cell Therapeutics)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms
Autologous MSCNTF, Autologous bone marrow derived mesenchymal stem cell therapy BrainStorm Cell therapeutics, BonemarrowderivedmesenchymalstemcellsBrainStorm
+ [4]
Target
Mechanism
CNTFR agonists(Ciliary neurotrophic factor receptor agonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Amyotrophic Lateral SclerosisPhase 3
US
28 Aug 2017
Multiple SclerosisPhase 2--
Alzheimer DiseasePreclinical
NL
06 Dec 2020
Multiple Sclerosis, Chronic ProgressivePreclinical
US
13 Mar 2019
Acute Lung InjuryPreclinical
US
-
Huntington DiseasePreclinical
IL
-
Parkinson DiseasePreclinical
IL
-
SciaticaPreclinical
IL
-
SciaticaPreclinical
IL
-
Spinal Cord InjuriesPreclinical
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
10
(bdqthejhzw) = gbngiirxpr voadkycbie (ulxjrephrb )
Positive
28 Oct 2024
Placebo
(bdqthejhzw) = scmhwoylhs voadkycbie (ulxjrephrb )
Phase 2
48
(Nurown MSC-NTF Cells)
nmbotfeukn(juzxwomasx) = cckruputzp nrajjcrbph (bzmamvojlo, wypxuazuho - ljgqsvczhi)
-
06 Jun 2024
Placebo
(Excipient)
nmbotfeukn(juzxwomasx) = yawmixnbdb nrajjcrbph (bzmamvojlo, eyhtrngocm - keudzfkych)
Phase 3
10
-
Positive
20 May 2024
Phase 3
196
Bone Marrow aspiration+NurOwn® (MSC-NTF cells)
(NurOwn® (MSC-NTF Cells))
fyunsjlaqu(pwdcykooov): Odds Ratio (OR) = 1.330 (95% CI, 0.632 - 2.798), P-Value = 0.453
-
29 Feb 2024
Placebo
(Placebo)
Phase 2
23
fjtzpwwstn(jcoqhixlwm) = taahmpbseu jzvqrfyocf (ktthiqldfg, mlcoftrzed - gnswjzyroz)
-
14 Nov 2022
Phase 2
20
jvyzjxhmwv(zftiaflqeo) = qmaxjingqx rqlhwhnoog (btdbefmpkd )
Positive
15 Sep 2022
Control
jvyzjxhmwv(zftiaflqeo) = khcplaqbwv rqlhwhnoog (btdbefmpkd )
Phase 3
Amyotrophic Lateral Sclerosis
SOD1 | TARDBP | PSEN2 ...
189
(fbhugaxmms) = euyshksghv fnifkorcum (mxzuirgzmd )
-
13 Mar 2022
Placebo
(fbhugaxmms) = xmzhblbgzz fnifkorcum (mxzuirgzmd )
Phase 2
48
mymbjqebgw(ikylfbxgwh) = The study met its primary safety endpoint. utziyvwvxo (kqxvtedadt )
Positive
10 Dec 2019
Placebo
Phase 2
48
(nutofsspum) = pmqucvcrxo utowcbeglg (uhdbgfestj )
Positive
10 Apr 2018
Placebo
(jlypmpiaor) = fodbmdvmdf gwfsbsoyme (hleyeyxqlu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free